237 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by Golden State Wealth Management LLC

Golden State Wealth Management LLC bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 237 shares of the life sciences company’s stock, valued at approximately $32,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC increased its position in Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after acquiring an additional 48,018 shares during the period. Primecap Management Co. CA lifted its holdings in Illumina by 3.6% during the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after buying an additional 87,599 shares during the period. Janus Henderson Group PLC increased its stake in shares of Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after buying an additional 625,245 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Illumina by 4.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock worth $164,334,000 after acquiring an additional 54,319 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after acquiring an additional 631,294 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ILMN. Barclays downgraded shares of Illumina from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $130.00 to $100.00 in a research report on Monday. Piper Sandler increased their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday. JPMorgan Chase & Co. boosted their price objective on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Morgan Stanley decreased their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday. Finally, TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and dropped their price target for the company from $177.00 to $140.00 in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $159.45.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $100.68 on Wednesday. The company has a market capitalization of $15.97 billion, a P/E ratio of -13.11 and a beta of 1.10. The company’s 50-day moving average is $135.90 and its 200 day moving average is $135.48. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. On average, equities research analysts forecast that Illumina, Inc. will post 4.42 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.